VBIOHealthcare · Biotechnology

VBIO Stock Forecast: Valion Bio, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026

$0.12

−0.25% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 2 of 100 as at 22 Aug 2026 — in the weakest quartile.

Market cap

$505,623.00

Ticker Nerd rank

2 / 100

Median analyst target

—

Analysts covering

Total return, dividends reinvested

−36.2%

−60.8%

YTD

−91.6%

−96.2%

From 52W high

−96.2%

From 52W low

0.0%

$0.12

$3.20

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

VBIO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Valion Bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026

2 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Revisions

Volatility

Growth

Accruals

Momentum

Value

Issuance

Quality

Size (99): Smaller than most of the companies we track.

Quality (1): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

VBIO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on VBIO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. VBIO appears on the weeks it earns a place.

Estimates

VBIO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Valion Bio, Inc. (VBIO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −0.0×
Price / sales: −5.9×
Price / book: 0.1×
EV / EBITDA: −1.1×

Growth & margins

Revenue growth (YoY): −100.0%
Earnings growth (YoY): −100.0%
Gross margin: —
Operating margin: 19354.7%
Net margin: 0.0%

Returns & dividend

Return on equity: −453.1%
Return on assets: −56.3%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

VBIO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology

Company	Market cap	TKN rank
VBIOValion Bio, Inc.	$505,623.00	2
CMNDClearmind Medicine, Inc.	$2.6M	8
ONCOOnconetix, Inc.	$2.6M	14
VRAXVirax Biolabs Group Ltd.	$2.5M	13
MTNBMatinas BioPharma Holdings, Inc.	$2.9M	46
ARTLArtelo Biosciences, Inc.	$3.2M	17
GNPXGenprex, Inc.	$3.2M	9

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Valion Bio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest VBIO news & analysis

Ukraine's Ministry Of Health Advances Entolimod Review Into Technical Assessment Phase

Accesswire · 13 Aug 2026positive

Ukraine's Ministry of Health accepted Entolimod's dossier for formal review on July 22, 2026, and has begun a technical assessment that includes its first round of questions on the physicochemical characterization of the drug product. A decision is possible as early as the fourth quarter of 2026, which could mark Entolimod's first national registration.

Why it matters — A VBIO watcher would care because a potential Q4 2026 decision in Ukraine could mark Entolimod's first national registration and open a pathway to strategic stockpiling and government procurement.

Valion Bio Announces U.S. Government-Funded Entolimod Studies Targeting Lethal Radiation-Induced GI Injury

Accesswire · 12 Aug 2026positive

Valion Bio announced U.S. government-funded entolimod studies under an AFRRI/NIAID program targeting lethal radiation-induced gastrointestinal injury. Entolimod has been delivered to AFRRI, IACUC approval was obtained, study animals are being acclimated, and dosing is expected to begin this week, with top-line therapeutic data expected in early fall.

Why it matters — VBIO watchers would follow this as evidence of forward progress in the company's key entolimod development program, backed by U.S. government funding and with clinical milestones on the near-term horizon.

FAQ

Frequently asked questions about VBIO stock

How does Ticker Nerd's model rank VBIO?

As at 22 Aug 2026, Valion Bio, Inc. ranks 2 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (99 of 100).

What is the VBIO stock forecast for 2030?

No analyst covering Valion Bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VBIO are extrapolating price history, which says nothing about the business.

How has VBIO stock performed over the past year?

Valion Bio, Inc. returned -96.2% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Valion Bio, Inc. do?

Valion Bio, Inc. operates as a late-stage biopharmaceutical company.

What is the latest news on VBIO?

The most recent item we track (Accesswire, 13 Aug 2026): "Ukraine's Ministry Of Health Advances Entolimod Review Into Technical Assessment Phase". Ukraine's Ministry of Health accepted Entolimod's dossier for formal review on July 22, 2026, and has begun a technical assessment that includes its first round of questions on the physicochemical characterization of the drug product. A decision is possible as early as the fourth quarter of 2026, which could mark Entolimod's first national registration.

Company

About Valion Bio, Inc.

Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.

CEO Mr. Michael Kevin Handley · 52 employees · United States · https://valionbio.com